In This Article:
Steven Cohen (Trades, Portfolio)'s Point72 Asset Management has recently made a significant investment in Syros Pharmaceuticals Inc (NASDAQ:SYRS), marking a new holding for the firm. On December 21, 2023, the firm purchased 1,471,771 shares of the biopharmaceutical company, with the transaction priced at $5.78 per share. This buy action represents a 0.03% impact on Cohen's portfolio, establishing a 5.70% ownership stake in Syros Pharmaceuticals.
Steven Cohen (Trades, Portfolio) and Point72 Asset Management: A Brief Overview
Steven A. Cohen, the Chairman and CEO of Point72, a prominent investment advisor, is known for his strategic investment decisions. With a career spanning over four decades, Cohen has established a reputation for his long/short equity strategy and a multi-manager platform that emphasizes fundamental bottom-up research. Point72 Asset Management, which evolved from S.A.C. Capital Advisors, focuses on delivering high-quality returns by investing in public markets, alongside ventures in AI-driven private equity and global venture capital.
Understanding Syros Pharmaceuticals
Syros Pharmaceuticals, a player in the biotechnology industry, specializes in gene control and cancer therapeutics. Since its IPO on June 30, 2016, the company has been engaged in the development of treatments that target non-coding regulatory regions of the genome. Operating solely in the United States, Syros Pharmaceuticals has a market capitalization of approximately $183.606 million. Despite being labeled as "Significantly Overvalued" by GuruFocus with a GF Value of $1.62, the stock has seen a 22.15% gain since Cohen's transaction, currently trading at $7.06.
Impact of Cohen's Trade on Portfolio
The acquisition of Syros Pharmaceuticals shares has a modest yet strategic impact on Cohen's portfolio. The 0.03% position size indicates a cautious entry, aligning with the firm's investment philosophy of informed macro investments. The trade has not only diversified the portfolio but also reflects Cohen's confidence in the biotechnology sector, which is one of the top sectors in Point72's holdings, alongside technology and healthcare.
Market Context and Valuation Insights
At the time of the trade, Syros Pharmaceuticals' shares were acquired at $5.78, which is significantly lower than the current price of $7.06. However, the stock's GF Value stands at $1.62, suggesting that it is currently overvalued. The stock's price to GF Value ratio is 4.36, indicating a premium compared to its intrinsic value. Despite this, the stock's recent performance may have been a contributing factor to Cohen's investment decision.